Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08/18 NEW SENIOR INVESTMENT : Gilead Sciences (GILD) Shareholder Underhill Investment ..
08/17 GILEAD SCIENCES : Announces U.S. FDA Priority Review Designation for Fixed-Dose ..
08/17 GILEAD SCIENCES : Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velp..
08/16 GILEAD SCIENCES : `s Newer Tenofovir Patents Might Aid Its HIV Franchise
08/16 GILEAD SCIENCES : to unveil 23-acre campus in La Verne this week
08/15 GILEAD SCIENCES : Announces U.S. FDA Priority Review Designation for Fixed Dose ..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/10 GILEAD SCIENCES : Announces U.S. FDA Priority Review Designation for Fixed-Dose ..
More news
News from SeekingAlpha
08/18 Hundred Thousand Dollars Income Portfolio - The Market Is Simply Overpriced
08/18 GILEAD : Road To $100
08/16 Very Cautious On AbbVie's Fundamentals
08/16 Half Million Dollar Income Portfolio - Keep Living The Dream
08/16 Gilead Stock In Revival Mode With Promising HIV Market And Stabilizing HCV Nu..
Financials ($)
Sales 2017 25 839 M
EBIT 2017 16 155 M
Net income 2017 10 609 M
Debt 2017 8 861 M
Yield 2017 2,94%
P/E ratio 2017 9,09
P/E ratio 2018 10,29
EV / Sales 2017 3,99x
EV / Sales 2018 4,33x
Capitalization 94 170 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 80,1 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES0.70%94 170
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
REGENERON PHARMACEUTICALS26.41%50 145
VERTEX PHARMACEUTICALS101.07%37 346
ACTELION23.02%30 302